In “Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma,” the authors review the most commonly targeted pathways in sarcoma and a selection of targeted therapies showing initial promise or approaching clinical use. Dr Harwood and his colleagues from the Arthur James Cancer Hospital at The Ohio State University start by reviewing the unsatisfactory state of current systemic therapy options for the most common bone and soft tissue sarcomas. They then review the major and minor pathways involved in sarcomagenesis, which have yielded potential targets for therapy. For some of these pathways, such as Hedgehog and IGF, inhibition of tumor growth has been demonstrated in vitro. Other targets, such as mTOR and VEGF, have agents that have progressed to phase II and even phase III trials, with response seen in multiple sarcoma subtypes.
![](https://freepngimg.com/download/social_media/63059-media-icons-telegram-twitter-blog-computer-social.png)
Stay updated, free articles. Join our Telegram channel
![](https://clinicalpub.com/wp-content/uploads/2023/09/256.png)
Full access? Get Clinical Tree
![](https://videdental.com/wp-content/uploads/2023/09/appstore.png)
![](https://videdental.com/wp-content/uploads/2023/09/google-play.png)